NeuroStar transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. The treatment targets areas that are involved in mood regulation and cognition. TMS is a targeted approach to treatment. Unlike antidepressant medications that affect the whole body, TMS focuses on specific parts of the brain.
TMS is effective for treatment-resistant depression and as a complementary therapy for obsessive-compulsive disorder (OCD). The history of TMS therapy offers insight into how different areas of scientific study can lead to treatment breakthroughs.
Magnetic fields have been used for medical therapy since the 18th century. Early experiments by Luigi Galvani helped Michael Faraday discover electromagnetic induction in 1831. This discovery led to Faraday equipment, which blocks external electric fields and electromagnetic radiation. Faraday’s discoveries influenced medical researchers to try magnetism in treatments.
It was not until the 1980s that scientists developed TMS and began using it in clinical research. At this time, Anthony Barker and his colleagues at the University of Sheffield in England made significant contributions to TMS development. In 1985, Barker’s team showed that the electromagnetic fields generated by a magnetic coil could stimulate the brain and influence brain cell activity. This development was important in the history of TMS since it provided a scientific demonstration of how electromagnetic fields could cause changes in your brain without surgery or an implant.
TMS has some side effects, most of which are typically short-lived and minor. The most common side effect you might experience is scalp discomfort, including tingling and headaches, where the magnetic coil is placed. These symptoms usually resolve after the first week of treatment and generally do not occur in the following weeks of therapy.
In the recent history of TMS, the therapy has proven effective in reducing the symptoms of treatment-resistant depression. TMS has also shown a response and remission rate that compares well to other established treatments without the side effects associated with medications. Clinical data shows that 63 percent of people who are treated with NeuroStar TMS have lower symptoms of depression, and some people experience complete remission.
When combined with TMS therapy, psychotherapy (talk therapy) could also provide further improvements to your treatment. However, traditional psychotherapy often requires lifestyle changes that could be difficult when you are experiencing depression symptoms, such as fatigue and loss of interest. TMS could offer relief from your symptoms and help you make the necessary changes for psychotherapy.
The FDA has cleared NeuroStar TMS for the treatment of major depressive disorder (MDD), and as an adjunctive therapy for OCD.
It may be challenging to find an effective treatment for MDD, and OCD. Without treatment, these conditions could significantly alter your lifestyle and reduce your quality of life.
We encourage you to call our office and schedule a consultation. The proven history of TMS therapy has significantly impacted mental health care. We can help you understand how TMS therapy could reduce your symptoms.
Adult Indications for Use
The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.
The NeuroStar Advanced Therapy System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
Adolescent Indications for Use
NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (15-21).
NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.
Important Safety Information
The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).
NeuroStar Advanced Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar Advanced Therapy has not been studied in patients who have not received prior antidepressant treatment.
**FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S score ≤2 at the end of treatment.
***Dunner DL, et al. (2014). J Clin Psychiatry, 75(12):1394-1401.